On August 18, ALI HEALTH fell 3.51% in regular trading, trading at HK$3.165/share, with turnover of HK$48.99 million. Multiple headwinds converged to pressure the stock toward UBS's target price of HK$3.1.

UBS previously maintained a \"sell\" rating on ALI HEALTH with a downward-revised target price of HK$3.1, with the current share price now approaching that level. Concurrently, UBS Group AG on August 10 sold 8.864 million shares at an average price of HK$3.5144, reducing its long position from 8.02% to 7.96%, representing continued institutional de-risking. Competitor JD Health reported robust first-half results with revenue of RMB 40.9 billion and adjusted operating profit growth of 40% year-on-year, intensifying market concerns over ALI HEALTH's competitive positioning.

The broader Internet and Direct Marketing Retail sector also traded lower, with JD HEALTH down 5.32%, PA GOODDOCTOR down 3.11%, JD-SW down 2.65%, MEITUAN-W down 2.4%, and BABA-W down 0.25%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)